Review paper

Fluorescent antibiotics for real-time tracking of pathogenic bacteria

Lu Miao a, Weiwei Liu a, b, Qinglong Qiao a, Xiaolian Li b, **, Zhaochao Xu a, *

a CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China
b State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, 116012, China

ARTICLE INFO

Article history:
Received 5 April 2020
Received in revised form
15 September 2020
Accepted 15 September 2020
Available online 18 September 2020

Keywords:
Fluorescent antibiotics
Live-cell tracking
Fluorophore
Pathogenic bacteria
Fluorescent imaging

ABSTRACT

The harm of pathogenic bacteria to humans has promoted extensive research on physiological processes of pathogens, such as the mechanism of bacterial infection, antibiotic mode of action, and bacterial antimicrobial resistance. Most of these processes can be better investigated by timely tracking of fluorophore-derived antibiotics in living cells. In this paper, we will review the recent development of fluorescent antibiotics featuring the conjugation with various fluorophores, and focus on their applications in fluorescent imaging and real-time detection for various physiological processes of bacteria in vivo.

© 2020 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Bacterial infections are one of the major causes of human diseases and death in the world. At present, bacterial infections have caused 700,000 deaths worldwide each year, and recent projections indicate that this annual death number may reach 10 million by 2050 [1,2]. This is mainly attributed to the emergence of multi-drugs resistant (MDR) bacteria stimulated by long-term overuse of antibacterial drugs for patients, especially in second-world countries [3,4]. For instance, the number of hospital infections caused by antimicrobial resistant bacteria has accounted for about 30% of the total number of pathogenic bacteria infections in hospitalized patients [5,6]. More timely and effective treatment is an urgent need for patients.

Antibiotics, one of the greatest discoveries of the 20th century, can effectively inhibit bacterial infections and reduce mortality. But with the increasing prevalence of MDR bacteria, many antibiotics including some potent broad spectrum drugs are no longer susceptible to most therapeuetic regimens [7]. Before developing new antibacterial drugs, we should first improve our fundamental understanding of how bacteria infect the human body, how drugs work with both bacteria and the human body, and the mechanism of bacterial resistance to drugs [8,9].

The fluorescent tracking capability of fluorophore-derived recognition element conjugate makes it an increasingly prevalent strategy used to monitor targets timely within organelles, whole cells, and entire animals. Recently, small-molecule fluorophores have been widely used in covalently linking to antibiotics, generally named fluorescent antibiotics. The monitoring of fluorescent antibiotics in living organisms has the potential in diagnosis of bacterial infections, elucidating antimicrobial agents mode of action, assessing drug toxicity, and examining bacterial antimicrobial resistance [10–16]. Fluorescent antibiotics generally divided into two types according to structural differences. One is auto-fluorescent antibiotics: antibiotics have functional groups with intrinsic fluorescence; the other is fluorophore-conjugated fluorescent antibiotics: a fluorophore was covalently linked to an existing antibiotic to produce a fluorophore–antibiotic compound.

Recently, Blaskovich’s group [17] reviewed the development of fluorescent antibiotics from the perspective of various antibiotics used for intracellular or cell wall targeting, and especially discussed the biological applications in how to fight antibiotic resistance. In this review, we mainly discuss the classification and composition of fluorescent antibiotics dependent on diverse fluorophores, and review the application in fluorescent imaging and real-time detection of pathogenic bacteria in vivo.
2. Autofluorescent antibiotics

Tetracycline is a classical intrinsic autofluorescent antibiotic (Fig. 1A). Early in the 1960s, tetracycline fluorescence was studied across bacterial membranes [18]. Both Escherichia coli (E. coli) and Bacillus cereus (B. cereus) with tetracycline were observed in dying guinea pig phagocytes under fluorescence microscopy. Furthermore, Glazier’s group [19] reported their initial studies on fermented product monitoring by fluorescence measurements of tetracycline signal in model fermentation media samples containing Streptomyces aureofaciens cell mass. In addition, some studies using autofluorescent antibiotics with fluorescent anthraquinone core, such as olivomycin and mithramycin (Fig. 1A), to stain DNA in cell mass. In addition, some studies using product monitoring by super-resolution (details in section 4.2) [18]. Both autofluorescent antibiotics generally showed weak fluorescence and poor stability, which limited their applications, especially in super-resolution fluorescent imaging of bacteria.

3. Fluorophore-antibiotic conjugates

3.1. Antibiotics

Antibiotics with recognition groups of fluorophore-antibiotic conjugates were used to specific recognition of target bacteria. Antibiotics interacted with bacteria by targeting essential survival processes such as inhibiting cell-wall synthesis and interfering with the synthesis of vital proteins or DNA [25]. There are several kinds of bacterial cell-wall related antibiotics, such as β-lactams, glycopeptides, lipopeptides, and polypeptides [26–29]. Among them, β-lactam antibiotics, such as penicillin (Fig. 1B) and ceftaroline, can inhibit the penicillglycans biosynthesis by covalently binding penicillin-binding proteins (PBPs) [30–34]. Vancomycin and ramoplanin treat Gram-positive infections by targeting lipid II (a precursor for bacterial peptidoglycan biosynthesis) of cell wall [27]. In addition, polymyxins as naturally occurring cyclic antibiotic lipopeptides are typically Gram-negative bacteria antibiotics and bind to lipid A on the bacterial outer membrane through electrostatic interaction (Fig. 1B) [28,35]. Antibiotics that act by targeting DNA or protein intra bacterial cell include macrolides, aminoglycosides, and quinolones etc. For example, erythromycin (macrolides) and kanamycin (aminoglycosides) act with ribosome of bacterial cell-wall related antibiotics, such as Bacillus (B. cereus), to block protein synthesis in the cells [36]. Trimethoprim (TMP) is the substrate of the intracellular protease dihydrofolate reductase (DHFR) [37]. The structures of them are shown in Fig. 1C. All of the antibiotics above have been linked to a fluorophore for studying in physiological processes of pathogenic bacteria.

3.2. Fluorophores

Commonly used fluorophores for fluorophore-antibiotics conjugates are displayed in Fig. 1D. They include nitrobenzofurazan (NBD), 7-(dimethylamino)-coumarin-4-acetic acid (DMACA), dansyl, boron-dipyrromethene (BODIPY), fluorescein, rhodamine, and cyanine 7(Cy7). Researchers bound these fluorophores or their derivatives to antibiotics for fluorescent monitoring antibiotics in bacteria or tracking target bacteria in live animals. The selection of fluorophore mainly depends on the physicochemical properties of fluorophore, such as size, biocompatibility, brightness, and sensing wavelength. The size and biocompatibility of fluorophores are likely to influence the antibacterial activity of antibiotics, which will be discussed in next section.

A fluorophore with higher brightness is considered to study detail physiological processes of pathogenic bacteria. BODIPY (ε = 9.1 x 10^4 M^-1 cm^-1, and ϕ = 0.94), fluorescein (ε = 9.3 x 10^4 M^-1 cm^-1, and ϕ = 0.95), or rhodamine (ε = 7.4 x 10^4 M^-1 cm^-1, and ϕ = 0.92) derived fluorophores are commercially available fluorophores with excellent extinction coefficient (ε) and quantum yield (ϕ). These fluorophores have been widely used in various biological imaging applications [38]. Furthermore, near-infrared (sensing wavelength in the region of 650–900 nm) fluorophores conjugated with antibiotic can be used for fluorescent imaging of bacterial infections in vivo (details in section 4.2) [39]. In addition, the fluorescent probe (the probe presenting turn-on or ratiometric signal while identifying target in situ) is created by linking one or two selective fluorophores to an antibiotic for real-time detection of target objects (details in section 4.3) [40,41].

3.3. Effect on antibacterial activity of antibiotics

In principle, it is important for fluorophore-derived antibiotics to maintain specificity and affinity to target. Unfortunately, the minimum inhibitory concentration (MIC, a commonly used measurement of the efficacy of an antibiotic) of most of fluorophore-derived antibiotics display an inevitable increasing trend (Table 1) [42–47]. This may be due to not only the reduced affinity of the derived antibiotic, but also the fact that the molecules cannot reach the target caused by the change in the physical properties of molecules. While fluorescein is a negatively charged fluorophore, Walker’s group [42] considered that the increased MICs of their fluorescein-derived antibiotics may be caused by the repulsive interactions of the compound to the cell wall (generally with amount of negative charges) and/or poor solubility of the compound. On the contrary, the relatively smaller and neutral BODIPY-derived antibiotics displayed lower MICs (10 μg/mL for BODIPY-Ramoplanin, 2.5 μg/mL for BODIPY-Vancomycin) than fluorescein derivatives (20 μg/mL for fluorescein-Ramoplanin, 20 μg/mL for fluorescein-Vancomycin). However, the MICs of BODIPY-derived antibiotics are still much higher than those of conventional antibiotics.

The introduction of fluorophore with smaller size would greatly reduce the influence on the properties of antibiotics. Li’s group [43,44,48] constructed fluorescent polymyxin probes by linking dansyl fluorophore to the N-terminus of polymyxin B. They consider that the small size of the dansyl group helps reduce the likelihood of negative steric effects on the pharmacophore of polymyxins. The MIC of dansyl-polymyxin B was 4 fold higher than that of polymyxin B (Table 1). And polymyxin mechanisms of action were explored by imaging of polymyxin interactions with kidney proximal tubular cells. Furthermore, the smaller fluorophores NBD (M = 164 g/mol) and DMACA (M = 261 g/mol) have been selected to combine with fluoroquinolone antibiotic ciprofloxacin in order to maximize the penetrance of the compound into the cytosol, particularly with Gram-negative bacteria [45,46]. However, not all antibiotics linked to small fluorophores maintain great antibacterial activity; the MIC of NBD-derived Trimethoprim (TMP-3C-TzNBD, MIC = 64 μg/mL) was much higher than that of TMP (MIC = 1 μg/mL) for Staphylococcus aureus (S. aureus) ATCC 25923 [47]. But the MIC value seemed to decrease with the prolonging of the linker (TMP-4C-TzNBD, MIC = 16 μg/mL; TMP-5C-TzNBD, MIC = 8 μg/mL). Nevertheless, DMACA-derived TMP did not display the same phenomenon, and all probes with different linkers showed lower antibacterial activity (MIC > 64 μg/mL). Authors considered the lack of whole cell activity was likely due to compound efflux.

4. Fluorescent tracking of pathogenic bacteria in vivo

Fluorescent tracking of pathogenic bacteria includes monitoring antibiotics in live bacteria or tracking target bacteria in live animals.
The fluorescent tracking ability depends on the response fluorescent signals of different fluorophores and the recognition of the antibiotics. Here, we mainly discuss various fluorophore-dependent fluorescent antibiotics utility in fluorescent imaging and real-time detection to better understand physiological processes of pathogenic bacteria in vivo.
4.1. Fluorescent imaging in live cells

Visualization study by fluorescent microscopy is critical to our understanding of bacterial growth and pathogenesis in their native environment. And fluorescent antibiotic is one of the essential tools to identify and track these physiological processes under fluorescent microscopy [49–52]. For example, Fluorescein-derived vancomycins have been used to visualize peptidoglycan biosynthesis in living cells [53,54]. Brightest staining was observed at the division site of Bacillus subtilis (B. subtilis) cells, which was predicted to be the site that peptidoglycan synthesis occurs, along with less apparent sidewall staining in a helical pattern. Fluorescein was the site that peptidoglycan synthesis occurs, along with less apparent sidewall staining in a helical pattern. Fluorescein was the site that peptidoglycan synthesis occurs, along with less apparent sidewall staining in a helical pattern. Fluorescein was the site that peptidoglycan synthesis occurs, along with less apparent sidewall staining in a helical pattern. Fluorescein was

| Fluorescent/Conventional antibiotics | Compound names in the references | MIC (µg/mL) | Species                  | Ref. |
|------------------------------------|---------------------------------|-------------|-------------------------|------|
| Ramoplanin                         | Ramo-4F1                       | 5           | Bacillus subtilis        | [42] |
| Fluorescein-Ramoplanin             | Ramo-4BDP                      | 20          |                         |      |
| Vancomycin                         | Van-F1                         | 0.13        |                         |      |
| Fluorescein-Vancomycin             | Van-BDP                        | 20          |                         |      |
| Polymyxin B                        | MIPS-9541                      | 1           | Pseudomonas aeruginosa   | [43] |
| Colistin                           | FADDI-285                      | 4           | Acinetobacter baumannii  | [44] |
| Linezolid                          |                                 | 4           | Enterococcus faecium     | [45] |
| DMACA-linezolid                    | Lz-tz-DMACA                    | 32          | Van A ATCC 51559         |      |
| NBD-linezolid                      | Lz-tz-NBD                      | 16          |                         |      |
| Ciprofloxacin                      |                                 | 0.313–0.06  | B. subtilis ATCC 6051    | [46] |
| DMACA-Ciprofloxacin                | Cipro-NBD 3                    | 4           |                         |      |
| DMACA-Ciprofloxacin                | Cipro-DMACA 4                  | 4           |                         |      |
| Trimethoprim                       |                                 | 1           | Staphylococcus aureus    | [47] |
| NBD-Trimethoprim                   | TMP-3C-TzNBD                   | 64          |                         |      |
| NBD-Trimethoprim                   | TMP-4C-TzNBD                   | 16          |                         |      |
| NBD-Trimethoprim                   | TMP-5C-TzNBD                   | 8           |                         |      |
| DMACA-Trimethoprim                 | TMP-3C-TzDMACA                 | >64         |                         |      |
| DMACA-Trimethoprim                 | TMP-4C-TzDMACA                 | >64         |                         |      |
| DMACA-Trimethoprim                 | TMP-5C-TzDMACA                 | >64         |                         |      |

DMACA: 7-(dimethylamino)-coumarin-4-acetic acid, NBD: nitrobenzofurazan.

The super-resolution structured illumination microscopic (SR-SIM) imagings of 4C-Tz-NBD in live S. aureus and E. coli have been reported by Phetsang et al. [47]. 4C-Tz-NBD was created by binding NBD to TMP antibiotic (Fig. 2A), and then S. aureus, wild type E. coli, and ΔtolC type E. coli (efflux pump deficient E. coli mutant strain) were stained with FM4-64FX, Hoechst 33342, and 4C-Tz-NBD, respectively. The bacteria were clearly imaged by SR-SIM (Figs. 2B–D), and more details have been observed. Cross sections of representative bacteria demonstrated that the 4C-Tz-NBD was largely localized inside the bacterial membrane when compared to the location of the red FM4-64FX dye (Figs. 2E and F). Moreover, 4C-Tz-NBD displayed higher cellular accumulation in ΔtolC-E. coli compared to wild type E. coli, which indicates that in normal bacteria TMP probe accumulation at a sufficiently high concentration to inhibit the DHFR target is prevented due to the removal by the TolC-dependent efflux pump system.

The brightness of NBD (ε = 1.54 × 10^4 M⁻¹ cm⁻¹, and Φ = 0.55) fluorophore was relatively lower than that of other probes, which may limit the investigation of detailed information [61]. BODIPY (ε = 9.1 × 10^4 M⁻¹ cm⁻¹, and Φ = 0.94), fluorescein (ε = 9.3 × 10^4 M⁻¹ cm⁻¹, and Φ = 0.95), or rhodamine (ε = 7.4 × 10^4 M⁻¹ cm⁻¹, and Φ = 0.92) are commercially available fluorophores with excellent light brightness, and widely employed in super resolution imaging applications [62]. BODIPY-derived penicillin V (a β-lactam antibiotic), BOCILLIN-FL (Boc-FL), is typical commercial probe. It was first developed in 1999 with the aim of detecting and studying the expression and folding of PBPs and TolC, and has been used for live-cell imaging. For example, 9a-NBD-azithromycin, a compound with the most similar pharmacokinetic profile to azithromycin, was used to study azithromycin’s in vivo distribution by confocal microscopy [55]. The fluorescent imaging of BODIPY-daptomycin in bacterial membrane revealed the mechanism of action of daptomycin on cell wall morphology and septation [56]. Lastly, Cy3-polymyxin B and Cy5-vancomycin (Cy3 and Cy5 are analogues of Cy7 fluorophore in Fig. 1D) can selectively labeled Gram-negative and Gram-positive bacteria in various kinds of complex bacterial samples [57].

However, the light diffraction of conventional fluorescence microscopes is limited to 200–300 nm and 500–700 nm in the lateral and axial dimensions, respectively. The size of bacteria is so small (1–10 μm) [58], and the spatial resolution of conventional fluorescence microscopes is insufficient for this. Thus, the utility of super-resolution microscopy has become essential to adequately visualizing the subcellular structures of these organisms [59,60].
Fig. 2. Super resolution imaging with different fluorescent antibiotics. (A) Structure of NBD-derived fluorescent antibiotic 4C-Tz-NBD [47]. SR-SIM fluorescence imaging of (B) S. aureus, (C) wild type E. coli, and (D) ΔtolC E. coli. And cross section of fluorescent imaging of (E) wild type E. coli and (F) ΔtolC E. coli: green, 4C-Tz-NBD; red, FM4-64FX; blue, Hoechst 33342. (G) Structures of fluorescent antibiotics Boc-FL and Ceph C-T [76]. 3D-SIM super-resolution microscope imaging of (H) B. subtilis and (I) S. pneumoniae IU 1945 PBPs after dual labeling with Ceph C-T (red) and Boc-FL (green) in live cells. NBD: nitrobenzofurazan, SR-SIM: super-resolution structured illumination microscopy, PBPs: penicillin-binding proteins.
that different populations of PBPs are active at discrete locations in the midcell during division of *B. subtilis* and *S. pneumoniae*.

### 4.2. Fluorescent imaging of bacterial infection in live animals

Optical imaging of bacterial infection in living animals is emerging as a powerful tool to study preclinical models of infectious disease [77–79]. Near-infrared (NIR) fluorophores with emission wavelengths in the region of 650–900 nm have been developed to target specific tissues that are otherwise difficult to image [80,81]. Oosten’s group [39] created a NIR probe vanco-800CW by covalently linking IRDye 800CW (a derivative of Cy7 fluorophore) to vancomycin. As shown in Fig. 3, the probe was successfully targeted to Gram-positive bacterial infections in living animals.
animals and a human cadaver. And it also can discriminate bacterial infections from sterile inflammation in vivo, indicating the sufficient resolution of the probe. The NIR fluorophores Cy5 and Cy5.5 as fluorescence resonant energy transfer donor-acceptor pair were further attached to cephalosporin constructing ratiometric substrate of β-Lactamase (the mechanism is described in next section), which was used for the real-time imaging of pulmonary infections and rapid quantification of bacteria in live mice [82]. The NIR fluorescent antibiotics were anticipated as a promising clinical optical imaging agent to fight against severe bacterial infections in the future.

4.3. Fluorescent real-time detection of bacteria

The fluorescent real-time detection requires a turn-on or ratiometric signal of the designed probe while recognizing a target. Turn-on probes exhibit no/weak fluorescence in their native states, and then they display a selective enhanced fluorescence after binding to objects. Rao and colleagues developed turn-on probes with high selectivity for Mtb protein β-Lactamase (BlAC, an enzyme produced by resistant bacteria that degrades-β-lactam antibiotics by destroying the cyclic core) for real-time and accurate detection of very low numbers of Mtb in patient sputum [83,84]. Furthermore, several groups have created ratiometric β-lactam probes by linking fluorescence resonant energy transfer (FRET) donor-acceptor fluorophores to β-lactam antibiotic. Zloknik and coworkers [85] first reported a ratiometric substrate of β-Lactamase in 1998 for real-time monitoring gene expression. 7-hydroxycoumarin and fluorescein as FRET donor-acceptor pair were attached to the 7 and 3’ positions of a cephalosporin, respectively, creating the FRET substrate CCF2 (Fig. 4). It emitted acceptor fluorescein fluorescence at 520 nm when excited at 7-hydroxycoumarin’s wavelength 409 nm. β-Lactamase could cleave CCF2 to separate the donor and acceptor. And then the donor emitted fluorescence at 447 nm. Using this ratiometric probe, β-Lactamase was detected in real-time to measure gene expression in single live mammalian cells with high sensitivity. In addition, various ratiometric fluorescent antibiotics based on cephalosporin were developed by attaching different fluorophores [40,86,87]. Ratiometric fluorescent probe C-2 with fluorescein and rhodamine donor-acceptor pair was used for screening microbes resistant to methoxyimino cephalosporins [87].

5. Conclusion

In this review, we have provided a brief introduction of fluorescent antibiotics for physiological studies on pathogenic bacteria in recent years. These studies were done by fluorescent tracking of antibiotics in live cells using autofluorescent antibiotics or fluorophore-antibiotics conjugates. Most probes have potential values for more extensive and in-depth research. Looking forward, the use of bio-specific small molecule probes with high specificity carries both a great potential and significant challenges. To date, the current understanding of microorganisms is still limited, and more excellent fluorophores should try to be incorporated into antibiotics. Meanwhile, super resolution fluorescence imaging is expected to study more details of the physiological processes of pathogenic bacteria. This may help researchers develop new antibiotics to prevent the potential outbreak of resident evil caused by super-resistant bacteria in the near future.

Declaration of competing interest

The authors declare that there are no conflicts of interest.

Acknowledgments

We are grateful for the financial support from the National Natural Science Foundation of China (21878286, 21908216, 21576043) and Dalian Institute of Chemical Physics (DIPCPI201938, DIPC1202006).

References

[1] C. Willyard, The drug-resistant bacteria that pose the greatest health threats, Nature 543 (2017) 15.
[2] K.E. Jones, N.G. Patel, M.A. Levy, et al., Trends in emerging infectious diseases, Nature 451 (2008) 990–993.
[3] M.N. Alekshun, S.B. Levy, Molecular mechanisms of antibacterial multidrug resistance. Cell 128 (2007) 1037–1050.
[4] J.V. Piddock, Reflecting on the final report of the O’Neill review on antimicrobial resistance, Lancet Infect. Dis. 16 (2016) 767–768.
[5] D.J. Payne, M.N. Gwynn, D.J. Holmes, et al., Drugs for bad bugs: confronting the challenges of antibiotic discovery, Nat. Rev. Drug Discov. 6 (2007) 29–40.
[6] Y.C. Lu, Y.S. Chuang, Y.Y. Chen, et al., Bacteria detection utilizing electrical conductivity, Biosens. Bioelecron. 23 (2008) 1856–1861.
[7] S.C. Davies, T. Fowler, J. Watson, et al., Annual report of the chief medical officer, infection and the rise of antimicrobial resistance, Lancet 381 (2013) 1606–1609.
[8] N.C. El Chakhoutoua, E. Saade, A. Ilovleva, et al., Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward ‘molecularly targeted’ therapy, Expert Rev. Anti Infect. Ther. 16 (2018) 89–110.
[9] M.N. Alekshun, S.B. Levy, Molecular mechanisms of antibacterial multidrug resistance. Cell 128 (2007) 1037–1050.
[10] J. Cama, A.M. Henney, M. Winterhalter, Breaching the barrier: quantifying antibiotic permeability across gram-negative bacterial membranes, J. Mol. Biol. 431 (2019) 3531–3546.
[11] E. Benito-Pena, M.C. Moreno-Bondi, G. Orellana, et al., Development of a novel and automated fluorescent immunosay for the analysis of beta-lactam antibiotics, J. Agric. Food Chem. 53 (2005) 6635–6642.
[12] J.O. Escobedo, Y.H. Chua, Q. Wang, et al., Live cell imaging of a fluorescent gentamicin conjugate, Nat. Prod. Commun. 7 (2012) 317–320.
[13] J. Vahist, V. Tiwari, R. Das, et al., Analysis of penicillin-binding proteins (PBPs) in carbapenem resistant acetobacter baumannii, Indian J. Med. Res. 133 (2011) 332–338.
[14] S.S. Gallagher, J. Choaraan, S.P. Darcy, et al., A trimethoprim-based chemical tag for live cell two-photon imaging, Chembiochem 11 (2010) 782–784.
[15] T. Jarzembskowsi, K. Wisniowska, A. Jozwik, et al., Heterogeneity of m-Lactamase could detect antibiotic resistance directly in bacterial cells in enterococcus faecalis and staphylococcus aureus strains (MRSa) characterized by flow cytometry, Curr. Microbiol. 59 (2009) 78–80.
[16] T. Jarzembskowsi, K. Wisniowska, A. Jozwik, Flow cytometry as a rapid test for detection of penicillin resistance in carbapenem resistant enterococcus faecalis and staphylococcus aureus, Curr. Microbiol. 57 (2008) 167–169.
[17] M.R.L. Stone, M.S. Butler, W. Phetsang, et al., Fluorescent antibiotics: new research tools to fight antibiotic resistance, Trends Biotechnol. 36 (2018) 523–536.
[18] H.G. Dubay, P. Riley, J.L. Showacre, Tetracycline fluorescence in permeability studies of membranes around intracellular parasites, Science 145 (1964) 163–165.
[19] J.J. Horvath, S.A. Glazier, Fluorescence measurement of tetracycline in model fermentation media samples containing streptomyces aureofaciens cell mass, Appl. Spectrosc. 50 (1996) 327–333.
[20] H.A. Crissman, A.P. Stevenson, D.J. Ollicky, et al., Detailed studies on the application of 3 fluorescent antibiotics for DNA staining in flow cytometry, Stain Technol. 53 (1978) 321–330.
[21] H.A. Crissman, R.A. Tobey, Specific staining of DNA with the fluorescent antibiotics, mithramycin, chromomycin, and olivomycin, Trends Cell Biol. 33 (1990) 97–103.
[22] G.C. Saunders, J.C. Martin, J.H. Jett, et al., Flow cytometric competitive-binding assay for determination of actinomycin-d concentrations, Cytometry 11 (1990) 311–313.
[23] G.R. Mikhailova, Z.E. Berdnikova, Use of the DNA-specific fluoresceochrome oligomycin for cell culture studies, Tissot. Genet. 25 (1991) 15–20.
[24] N.L. Vekshin, V.I. Kovalyev. Nucleotide carriers for anti-tumour antibiotic antibiotics, J. Biochem. 159 (2013) 59–66.
[25] A. Gupta, S. Mumtaz, C.H. Li, et al., Combating antibiotic-resistant bacteria using nanomaterials, Chem. Soc. Rev. 48 (2019) 415–427.
[26] D.A. Dick, J.F. Fisher, S. Mobsahery, Cell-wall recycling of the gram-negative bacteria and the nexus to antibiotic resistance, Chem. Rev. 118 (2018) 5952–5984.
[27] E. Breukink, B. de Kruijff, Lipid II as a target for antibiotics, Nat. Rev. Drug Discov. 5 (2006) 321–332.
[28] T. Velkov, K.D. Roberts, R.L. Nation, et al., Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics, Future Microbiol. 8 (2013) 711–724.
[29] A.B. Shapiro, Investigation of beta-lactam antibiotic drugs, beta-lactamases, and penicillin-binding proteins with fluorescence polarization and
anisotropy: a review, Methods Appl. Fluoresc. 4 (2016) 024002.
30. P. Machelouef, C. Contreras-Martel, V. Job, et al., Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes, FEMS Microbiol. Rev. 30 (2006) 673–691.
31. W. Vollmer, U. Bertsche, Murein (peptidoglycan) structure, architecture and biosynthesis in Escherichia coli, Biochim. Biophys. Acta 1778 (2008) 1734.
32. E. Sauvage, F. Kerff, M. Terrak, et al., The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis, FEMS Microbiol. Rev. 32 (2008) 234–258.
33. A. Rogy, G. Cabot, I. Sanchez-Diener, et al., Role of pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins in AmpC expression, beta-lactam resistance, and peptidoglycan structure, Antimicrob. Agents Chemother. 59 (2015) 3925–3934.
34. H. Moisan, M. Pruneau, F. Malouin, Binding of ceftaroline to penicillin-binding proteins of staphylococcus aureus and Streptococcus pneumoniae, J. Antimicrob. Chemother. 65 (2010) 713–716.
35. A. Clausell, F. Rabanal, M. Garcia-Subirats, et al., Membrane association and contact formation by a synthetic analogue of polymyxin B and its fluorescent derivatives, J. Phys. Chem. B 110 (2006) 4465–4471.
36. R. Vince, D. Weiss, S. Pestka, Binding of n-substituted rhodamineylamines to ribosomes, Antimicrob. Agents Chemother. 9 (1976) 131–136.
37. N.T. Calloway, M. Choo, A. Sano, et al., Optimized fluorescent trimethoprim derivatives for in vivo protein labeling, Chembiochem 8 (2007) 767–774.
38. R.P. Haugland, The Handbook: A Guide to Fluorescent Probes and Labeling Technologies, 10th Edition, Molecular Probes, Eugene, OR, 2005.
39. M. Dosten, T. J. A. Gazendam, et al., In vivo imaging of invasive- and biomaterial-associated bacterial infections using fluorescently labelled vancomycin, Nat. Commun. 4 (2013) 2584.
40. W. Mao, X. Jiang, Z. Jiang, et al., Specific detection of extended-spectrum beta-Lactamase activities with a ratiometric fluorescent Probe, Chembiochem 18 (2017) 1990–1994.
41. H. Chen, C. Liu, D. Chen, et al., Bacteria-targeting conjugates based on anti-microbial peptide for bacteria diagnosis and therapy, Mol. Pharm. 12 (2015) 2505–2516.
42. K. Thiyanont, T. Doan, M.B. Lazarus, et al., Imaging peptidoglycan biosynthesis in bacillus subtilis with fluorescent antibiotics, P. Nat. Acad. Sci. USA 103 (2006), 11033–11038.
43. B. Yun, M.A.K. Azad, C.J. Nowell, et al., Cellular uptake and localization of polymyxins in renal tubular cells using rationally designed fluorescent probes, Antimicrob. Agents Chemother. 59 (2015) 7485–7496.
44. Y. Yan, K.D. Roberts, P.E. Thompson, et al., Design and evaluation of novel polymyxin fluorescent probes, Sensors 17 (2017) 2598.
45. W. Phetsang, M.A.T. Blaskovich, M.S. Butler, et al., An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants, Bioorg. Med. Chem. 22 (2014) 4490–4498.
46. M.R.L. Stone, M. Masi, W. Phetsang, et al., Fluoroquinolone-derived fluorescent probes for studies of bacterial penetration and efflux, MedChemComm 10 (2019) 501–906.
47. W. Phetsang, R. Peligton, M.S. Butler, et al., Fluorescent trimethoprim conjugate probes to assess drug accumulation in wild type and mutant escherichia coli, ACS Infect. Dis. 2 (2016) 688–701.
48. R.L. Soon, T. Veilov, F. Chiu, et al., Design, synthesis, and evaluation of a new fluorescent probe for measuring peptidoglycan-lipoprotein association in interactions, Anal. Biochem. 409 (2011) 273–283.
49. O. Kocaoglu, E.C. Carlson, Progress and prospects for small-molecule probes of beta-lactamase reporter enzyme, Antimicrob. Agents Chemother. 59 (2015) 3548–3555.
50. O. Kocaoglu, R.A. Calvo, L.-T. Sham, et al., Selective penicillin-binding protein imaging probes reveal substructure in bacterial cell division, ACS Chem. Biol. 7 (2012) 1746–1753.
51. A. Bunschoten, M.M. Welling, M.F. Termaat, et al., Development and prospects of dedicated tracers for the molecular imaging of bacterial infections, Bioconjugate Chem. 24 (2013) 1971–1989.
52. H. Zhou, Y. Xiao, X. Hong, New NBR-8 dyes without a benzothiadiazole core, Chin. Chem. Lett. 29 (2018) 1425–1427.
53. J. Xu, L. Shang, Emerging applications of near-infrared fluorescent metal nanoclusters for biological imaging, Chin. Chem. Lett. 29 (2018) 1436–1444.
54. G. Hong, A.L. Antaris, H. Dai, Near-infrared fluorescent probes for biomedical imaging, Nat. Biomed. Eng. 1 (2017), 0016.
55. Z. Chang, F. Liu, L. Wang, Near-infrared dyes, Nanomaterials and proteins, Chin. Chem. Lett. 30 (2019) 1856–1888.
56. Y. Kong, H. Yao, H. Ren, Chlorin e6: an intracellular tumor targeting conjugate with endogenous beta-lactamase reporter enzyme fluorescence in live mice, P. Natl. Acad. Sci. USA 107 (2010) 12239–12244.
57. H. Xie, J. Mire, Y. Kong, et al., Rapid point-of-care detection of the tuberculosis pathogen using a Bla-specific fluorescent probe, Nat. Chem. 4 (2012) 802–809.
58. Y. Cheng, H. Xie, P. Sule, et al., Fluorescent probes with substitutions at the 2 and 7 Positions of cephalosporin are highly Bla-specific for rapid micobacterium tuberculosis detection, Angew. Chem. Int. Ed. Engl. 53 (2014) 9360–9364.
59. G. Zlokarnik, P.A. Negulescu, T.E. Knapp, et al., Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter, Science 279 (1998) 84–88.
60. A. Rukavishnikov, K.R. Gee, I. Johnson, et al., Fluorescent probes for selective labeling of Gram-negative and Gram-positive bacteria in living microbialis, Sci. China Life Sci. 21 (2012) 782–789.
61. L. Miao, W. Liu, Q. Qiao et al. Journal of Pharmaceutical Analysis 10 (2020) 444–451
62. F. Deng, Z. Xu, Heteroatom-substituted rhodamine dyes: structure and spectroscopic properties, J. Chromatogr. A 1385 (2013) 1385–1391.